ENSC

Over the past six months, Ensysce Biosciences' stock has significantly declined. Key events include securing IRB approval for a clinical study, registering resale shares, closing a preferred and warrant deal, a board member's exit, reporting financial results with a net loss, initiating a review of strategic alternatives, expanding its global patent portfolio, shareholders approving key corporate actions, and PF614-MPAR receiving FDA Breakthrough Therapy designation.